How does Nandrolone Decanoate bind to the androgen receptor differently from testosterone?

Nandrolone binds the androgen receptor (AR) with approximately 2.4 times the affinity of testosterone in competitive binding assays, yet it produces a weaker androgenic signal because its AF-2 activation surface interaction differs from testosterone's. The absence of the C-19 methyl group alters the ligand-receptor conformational fit, favouring anabolic genomic transcription while limiting classical androgenic activation in tissues like the prostate and scalp.

What does the 19-nor chemical structure mean for Nandrolone's effects in the body?

The 19-nor designation means a methyl group has been removed from position 19 of the testosterone carbon skeleton. This single structural change redirects the compound's metabolic fate — instead of converting to potent DHT via 5-alpha-reductase, Nandrolone converts to dihydronandrolone (DHN), which has far lower AR affinity in androgen-sensitive tissues. The result is a measurably anabolic compound with reduced androgenic burden per equivalent dose.

Why does Nandrolone have a lower androgenic impact on tissues like scalp and prostate than testosterone?

In 5-alpha-reductase-rich tissues — scalp follicles, sebaceous glands, and prostate epithelium — testosterone is amplified into DHT, a high-potency androgen. Nandrolone follows the same enzyme pathway but produces DHN instead, which radioimmunoassay data shows binds the AR at significantly reduced affinity. This metabolic detour mechanistically explains the lower incidence of scalp and prostate-related androgenic effects reported in Nandrolone clinical literature compared to testosterone-equivalent dosing.

Why are single-dose 1 ml ampoules preferable for maintaining sterility with injectable Nandrolone Decanoate?

Single-dose glass ampoules are hermetically sealed and opened only once, eliminating the repeated needle penetration of a rubber septum that can introduce particulate matter or microbial contamination over time. Each Elbrus Pharmaceuticals ampoule contains one precisely measured 300 mg dose; once broken, the full volume is drawn and no residual product is stored, ensuring every injection uses a sterile, uncompromised preparation from first draw to last.

How should Elbrus Pharmaceuticals Nandrolone Decanoate 10x1ml ampoules be stored to maintain potency?

Store ampoules at 15–25 °C, away from direct light and moisture; Type I borosilicate glass provides chemical inertness but UV exposure can degrade the oil carrier and active compound over time. Do not refrigerate — cold temperatures can cause the oil vehicle to thicken or the API to precipitate, making accurate dosing unreliable. Inspect each ampoule visually before use: discard any ampoule showing particulate matter, cloudiness, or a compromised seal. (2) angle_used

Optimal Dosage

Elbrus Pharmaceuticals

Nandrolone Decanoate 300mg/ml 10x1ml Ampullen by Elbrus Pharmaceuticals

Name: Nandrolone Decanoate 300mg/ml 10x1ml Ampoules by Elbrus Pharmaceuticals
Brand: Elbrus Pharmaceuticals
SKU: INJ-NAND-ELB-300-007
Price: 60.00 EUR
Availability: InStock

Elbrus Pharmaceuticals Nandrolone Decanoate 300 mg/ml is a 19-nor-testosterone-derived anabolic-androgenic steroid formulated as ten individual 1 ml single-dose ampoules, distinguished by its selective androgen receptor affinity and reduced DHT-conversion profile compared to testosterone-based compounds. Each ampoule delivers a precisely measured 300 mg dose, removing the risk of contamination or dose drift associated with multi-draw containers. Quality assurance at Elbrus Pharmaceuticals is enforced through: GMP-certified production lines, HPLC-confirmed active pharmaceutical ingredient (API) purity, and LAL endotoxin testing on every finished batch.

€60.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Androgen receptor occupancy at roughly 2.4× testosterone affinity drives measurable nitrogen retention and protein synthesis.
5-alpha-reductase conversion produces DHN rather than DHT, reducing androgenic load in scalp and prostate tissues.
300 mg/ml concentration per ampoule supports precise receptor-saturation dosing without volumetric estimation errors.
Ten individual hermetically sealed ampoules guarantee single-use sterility for every injection session.
Genomic upregulation of myosin heavy-chain isoforms supports sustained skeletal muscle contractile protein accrual.
Renal erythropoietin stimulation via AR-mediated signalling improves oxygen-carrying capacity and workout recovery.
HPLC-verified API and LAL endotoxin testing provide batch-level confirmation of purity and injectable safety.

Dosing is structured around androgen receptor saturation windows established in published pharmacological literature. All doses are for adult males; females should not use injectable Nandrolone Decanoate at these concentrations.

Phase	dosage	Note
Introductory / Receptor Priming	150–200 mg/week (0.5–0.67 ml)	Allows AR sensitivity assessment before full saturation; minimises initial axis suppression while establishing baseline response.
Optimal Dosing — Anabolic Phase	300–400 mg/week (1.0–1.33 ml)	Aligns with the AR saturation range most frequently cited in bodybuilding pharmacology literature; delivers maximal anabolic-to-androgenic ratio.
Advanced / High-Volume Training Block	400–600 mg/week (1.33–2.0 ml)	Receptor occupancy approaches saturation ceiling; incremental anabolic gains diminish while HPTA suppression and prolactin elevation risk increase proportionally.
Taper / Pre-PCT Drawdown	100–150 mg/week (0.33–0.5 ml)	Gradual reduction lowers average AR occupancy, allowing partial HPG axis signalling to resume before exogenous compound is fully cleared.

Key takeaways

Understand Nandrolone's AR-binding affinity as the primary driver of its anabolic output.
Recognise DHN formation as the mechanism reducing androgenic effects in sensitive tissues.
Confirm GMP and HPLC certification before selecting any injectable nandrolone product.
Choose single-dose ampoules to eliminate multi-draw contamination risk entirely.
Track androgen receptor signalling markers alongside standard bloodwork during cycles.

Nandrolone Decanoate as an Androgen Receptor Agonist: Mechanism of Action

Nandrolone Decanoate is a 19-nor-testosterone ester whose pharmacological activity originates from high-affinity, selective binding to the intracellular androgen receptor (AR), triggering downstream genomic transcription that promotes nitrogen retention, protein synthesis, and erythropoiesis. Once the decanoate ester undergoes enzymatic hydrolysis in systemic circulation, free Nandrolone enters target cells and occupies the AR ligand-binding domain with a binding affinity estimated at roughly 2.4 times that of testosterone in standardised competitive-binding assays. This elevated receptor occupancy — without proportional androgenic signalling — arises from Nandrolone's structural absence of the C-19 methyl group, which alters the conformational interaction between the steroid and the androgen receptor's activation function-2 (AF-2) surface. The practical consequence is a pharmacological profile weighted toward anabolic output relative to androgenic activation.

DHT Pathway Divergence and Tissue Selectivity

Nandrolone diverges critically from testosterone at the 5-alpha-reductase step. Compared to testosterone — which converts to the potent androgen dihydrotestosterone (DHT) via 5-alpha-reductase in scalp, prostate, and skin — Nandrolone undergoes reductive metabolism to dihydronandrolone (DHN), a compound with significantly weaker AR-binding capacity in androgen-sensitive tissues. Radioimmunoassay studies published in endocrinology literature confirm that DHN binds the AR at a fraction of DHT's affinity, effectively lowering androgenic burden in 5-alpha-reductase-rich tissues. This mechanistic divergence is why clinicians and researchers have consistently reported a more favourable androgenic side-effect profile per milligram of anabolic stimulus when using Nandrolone-based preparations versus testosterone esters at equivalent AR-stimulating doses.

Intracellular Signalling Cascade and Anabolic Outcomes

Once Nandrolone occupies the AR, the ligand-receptor complex translocates to the nucleus, where it acts as a transcription factor by binding androgen response elements (AREs) on target gene promoters. Nandrolone receptor activation upregulates genes encoding contractile proteins, including myosin heavy-chain isoforms, supporting skeletal muscle hypertrophy measurable by nitrogen balance studies. The compound also stimulates renal erythropoietin (EPO) secretion through AR-mediated signalling in peritubular cells — a mechanism documented in clinical haematology and confirmed by haematocrit changes in controlled osteoporosis trials. Elbrus Pharmaceuticals' 300 mg/ml concentration in individual 1 ml ampoules aligns with standard receptor-saturation dosing windows, allowing users to titrate weekly AR exposure accurately without volumetric guesswork.

Usage

Verify the ampoule's seal integrity and inspect the oil for clarity and absence of particulates before breaking the neck at the scored line.
Draw the calculated dose volume into a fresh, sterile syringe using an 18-gauge draw needle to reduce introduction of glass particles; switch to a 21–23-gauge injection needle before administration.
Select a deep intramuscular injection site — gluteus maximus or vastus lateralis — chosen for their capacity to absorb oil-volume depot injections without significant discomfort.
Aspirate briefly after needle insertion to confirm the needle tip is not in a vessel; then inject slowly at approximately 1 ml per 10 seconds to distribute the oil depot evenly in the muscle fascia.
Divide the weekly dose across two equal injections (e.g., Monday and Thursday) to maintain more consistent plasma Nandrolone levels throughout the cycle, reducing peak-to-trough fluctuation that could affect AR occupancy stability.
Discard each opened ampoule and all used equipment immediately — single-dose ampoules are not rated for partial use or re-storage; document injection date, site, and dose volume in a training log for accurate monitoring.

Warnings

contraindications: Contraindicated in individuals with diagnosed or suspected androgen-sensitive malignancies, including prostate carcinoma.

Not for use in women of childbearing potential; Nandrolone is classified as a virilising agent and carries teratogenic risk.

Individuals with hepatic impairment, nephrotic syndrome, or hypercalcaemia should not use this compound without specialist medical supervision.

Contraindicated alongside anticoagulant therapy — Nandrolone potentiates anticoagulant effect, increasing haemorrhagic risk.

side_effects: HPTA suppression leading to endogenous testosterone reduction — onset within the first weeks of use at standard doses.

Elevated serum prolactin levels secondary to 19-nor compound use; may manifest as lactation or sexual dysfunction if unmanaged.

Fluid retention and oedema, particularly at higher weekly doses exceeding 400 mg, driven by aldosterone-pathway interaction.

Potential for mood alteration, including aggression or depressive episodes, linked to altered androgen-to-oestrogen signalling during use.

monitoring: Baseline and on-cycle serum testosterone, LH, FSH, and prolactin panels are essential — minimum every 6–8 weeks during active use.

Monitor haematocrit and haemoglobin; Nandrolone's EPO-stimulating mechanism can raise red blood cell mass above safe thresholds.

Track hepatic enzyme panels (ALT, AST) and lipid profiles (LDL/HDL ratio) at each monitoring interval.

Blood pressure monitoring is advised; fluid retention can elevate systolic and diastolic readings during the cycle.

pct: Initiate PCT no earlier than 3–4 weeks after the final injection to allow sufficient plasma Nandrolone clearance before SERM therapy begins.

Standard PCT protocols employ Tamoxifen (Nolvadex) at 40 mg/day for the first two weeks, reducing to 20 mg/day for weeks three and four.

Prolactin management with a dopamine agonist (cabergoline) should be considered where serum prolactin was elevated during cycle.

Repeat full hormonal bloodwork four weeks post-PCT to confirm HPG axis recovery before considering any subsequent cycle.

Frequently asked questions

How does Nandrolone Decanoate bind to the androgen receptor differently from testosterone?: Nandrolone binds the androgen receptor (AR) with approximately 2.4 times the affinity of testosterone in competitive binding assays, yet it produces a weaker androgenic signal because its AF-2 activation surface interaction differs from testosterone's. The absence of the C-19 methyl group alters the ligand-receptor conformational fit, favouring anabolic genomic transcription while limiting classical androgenic activation in tissues like the prostate and scalp.
What does the 19-nor chemical structure mean for Nandrolone's effects in the body?: The 19-nor designation means a methyl group has been removed from position 19 of the testosterone carbon skeleton. This single structural change redirects the compound's metabolic fate — instead of converting to potent DHT via 5-alpha-reductase, Nandrolone converts to dihydronandrolone (DHN), which has far lower AR affinity in androgen-sensitive tissues. The result is a measurably anabolic compound with reduced androgenic burden per equivalent dose.
Why does Nandrolone have a lower androgenic impact on tissues like scalp and prostate than testosterone?: In 5-alpha-reductase-rich tissues — scalp follicles, sebaceous glands, and prostate epithelium — testosterone is amplified into DHT, a high-potency androgen. Nandrolone follows the same enzyme pathway but produces DHN instead, which radioimmunoassay data shows binds the AR at significantly reduced affinity. This metabolic detour mechanistically explains the lower incidence of scalp and prostate-related androgenic effects reported in Nandrolone clinical literature compared to testosterone-equivalent dosing.
Why are single-dose 1 ml ampoules preferable for maintaining sterility with injectable Nandrolone Decanoate?: Single-dose glass ampoules are hermetically sealed and opened only once, eliminating the repeated needle penetration of a rubber septum that can introduce particulate matter or microbial contamination over time. Each Elbrus Pharmaceuticals ampoule contains one precisely measured 300 mg dose; once broken, the full volume is drawn and no residual product is stored, ensuring every injection uses a sterile, uncompromised preparation from first draw to last.
How should Elbrus Pharmaceuticals Nandrolone Decanoate 10x1ml ampoules be stored to maintain potency?: Store ampoules at 15–25 °C, away from direct light and moisture; Type I borosilicate glass provides chemical inertness but UV exposure can degrade the oil carrier and active compound over time. Do not refrigerate — cold temperatures can cause the oil vehicle to thicken or the API to precipitate, making accurate dosing unreliable. Inspect each ampoule visually before use: discard any ampoule showing particulate matter, cloudiness, or a compromised seal. (2) angle_used

Manufacturer

Elbrus Pharmaceuticals operates its injectable manufacturing lines under full GMP certification, with compliance verified against internationally recognised pharmaceutical manufacturing standards applicable to parenteral dosage forms. For Nandrolone Decanoate production, the GMP framework is applied at every stage of manufacture — from raw material receipt through to finished-product release — with ISO-aligned environmental controls governing cleanroom classification, personnel gowning protocols, and aseptic fill-finish conditions. Finished-product release testing at Elbrus encompasses HPLC-based potency confirmation, ensuring the declared 300 mg/ml concentration is verified analytically rather than assumed from formulation input. LAL (Limulus Amebocyte Lysate) endotoxin testing is conducted on each batch as a mandatory injectable safety criterion, and sterility testing completes the release panel before any ampoule reaches distribution. These certification-driven quality standards are maintained as standing obligations, not project-specific measures.

Product details

Brand	Elbrus Pharmaceuticals
Active ingredient	nandrolone decanoate
Also known as	Deca Durabolin, Deca, Nandrolone Decanoate, Nandrolonee Decanoatee, Elbrus Pharmaceuticals Deca Durabolin
Strength	300 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-NAND-ELB-300-007

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Decandrol 200mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Decandrol 200mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Decandrol is an injectable anabolic steroid produced by Balkan Pharmaceuticals, delivering Nandrolone Decanoate at 200 mg per millilitre across a ten-ampoule pack — a formulation directly rooted in over six decades of pharmaceutical and clinical development of the nandrolone molecule. First synthesised in 1960, Nandrolone Decanoate evolved from early research compounds into one of the most studied anabolics in sports medicine and endocrinology literature. Quality assurance at the Chișinău facility is governed by GMP compliance, with each production batch subjected to HPLC potency verification and LAL endotoxin testing before release.

€44.00

High Concentration

Deca-Durabolin 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Beligas Pharmaceuticals Deca-Durabolin delivers 300 mg of Nandrolone Decanoate per millilitre in a 10 ml multi-dose vial, purpose-engineered for integration into structured, periodised cycle protocols where consistent anabolic stimulus and joint support are programmed across distinct training phases. At 300 mg/ml, each vial provides 3,000 mg of active compound — enough to sustain a full intermediate-length cycle from kickstart to planned taper without mid-cycle restocking. Quality assurance is baked into every stage of production: HPLC-verified potency, LAL endotoxin testing on each batch, and full-cycle GMP compliance underpin the consistency that modern cycle planners demand.

€52.00

Decadubol-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Decadubol-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Decadubol-250 is a long-chain esterified anabolic injectable in which Nandrolone Decanoate at 250 mg/ml is designed around an extended pharmacokinetic release profile, giving the compound one of the longest circulating half-lives among injectable androgens. The decanoate ester slows hydrolysis after intramuscular depot formation, sustaining active Nandrolone plasma concentrations across a 6–8-day elimination window. Quality assurance is embedded at every production step: HPLC-verified potency, LAL endotoxin screening, and GMP-compliant fill-finish — all carried out by BM Pharmaceuticals.

€45.00

Trusted Brand

DecaTrex 350mg/ml 10ml Vial by Concentrex Labs

DecaTrex by Concentrex Labs delivers Nandrolone Decanoate at 350 mg/ml in a 10 ml multi-dose vial, purpose-built for athletes who structure their year around defined cruise and blast phases rather than standalone cycles. Its elevated concentration minimises injection volume during high-dose blast windows while keeping weekly cruise doses manageable with a single, low-volume pull. Every production batch passes HPLC quantification for concentration accuracy and LAL endotoxin testing for sterility assurance; GMP-certified manufacturing protocols govern each step from API weighing through final vial sealing.

€52.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00